MedTrace Logo

Intravenous Terbutaline in Severe Status Asthmaticus

NCT00750568 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 36

Last updated 2008-09-10

No results posted yet for this study

Summary

Terbutaline is a medication that is used to treat serious asthma attacks (status asthmaticus). The purpose of this study is to determine if terbutaline is effective and safe when given as a continuous intravenous infusion to children ages 2 years to 18 years of age. Children participating in this study are inpatients in the Intensive Care Unit with a diagnosis of status asthmaticus and are receiving terbutaline as part of their routine care. Blood samples and physiological assessments will be used to determine how the body is using terbutaline and how well it is working.

Conditions

  • Status Asthmaticus

Sponsors & Collaborators

  • Wayne State University

    lead OTHER

Principal Investigators

  • Kevin Valentine, M.D. · Children's Hospital of Michigan

  • Mary Lieh-Lai, M.D. · Children's Hospital of Michigan; Wayne State University

Eligibility

Min Age
2 Years
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-10-31
Primary Completion
2009-08-31
Completion
2009-08-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00750568 on ClinicalTrials.gov